IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re:

Yang et al.

Confirmation No.:

6917

Serial No.:

10/538.134

Filing Date:

June 9, 2005

Patent No.: 7,271,172 B2

Issue Date:

September 18, 2007

Title:

PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5

ANTAGONISTS

Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR §1.322

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent in accordance with 37 CFR §1.322.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith.

The Commissioner is authorized to charge any fees or to credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted.

Bonnie L. Deppenbróck Attorney for Patentee Registration No. 28,209

Customér No. 23347

GlaxoSmithKline

Corporate Intellectual Property Department

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone:

(919) 483-1577

Facsimile: (919) 483-7988

ELECTRONICALLY FILED USING THE EPS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON October 5, 2007.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Restriction Act of 1995, no persons are required to respond to a policition of information unless it displays a valid CMM control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

: 7,271,172 82

Attorney Docket No.: PU4976USw

Page I of I

APPLICATION NO. 10/538.134

ISSUE DATE

: September 18, 2007

INVENTOR(S)

: Yang et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

The chemical structure of Claim 3 (Column 115, Lines 10-15) should read as follows:

$$R^{3} = (Y)_{a} = N \xrightarrow{B} X = N \xrightarrow{A} X = N$$

Claim 3 (Column 115, Line 40) should read as follows:

- each R⁶ is independently selected from the group consisting of halogen, -CF₃, --

Claim 3 (Column 115, Line 61) should read as follows:

- each R⁷ is independently selected from the group consisting of halogen, -CF₃₀ --

Claim 3 (Column 116, Lines 21-23) should read as follows:

- each R^o is independently selected from the group consisting of hydrogen, alkyl, alkenyl, sikynyl, cycloalkyl, carbocyclylaikyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, and het- --

Claim 5 (Column 116, Lines 46-47) should read as follows:

- 5. The compound of claim 3 wherein R1 is phenyl monoor di-substituted with halogen. --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GLAXOSMITHKLINE

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTÓ to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including galhering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.